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SENSITIVITY AND SPECIFICITY OF 
INTRATHECAL FLUORESCEIN AND WHITE 
LIGHT EXCITATION FOR DETECTING 
INTRAOPERATIVE CEREBROSPINAL FLUID 
LEAK IN ENDOSCOPIC SKULL BASE 
SURGERY: A PROSPECTIVE STUDY[2]
Study Question: What is the diagnostic value of 
intrathecal fluorescein to identify an intraoperative 
cerebrospinal fluid (CSF) leak during endoscopic 
endonasal skull base surgery?
The authors review a prospectively accrued database 
of consecutive patients to assess the effectiveness of 
the off‑label routine use of intrathecal fluorescein to 
detect an intraoperative cerebrospinal fluid (CSF) leak 
during endoscopic endonasal skull base surgery. Patients 
were pretreated with intravenous dexamethasone and 
diphenhydramine prior to administration of 25 mg 
of fluorescein injected immediately before surgery via 
lumbar puncture or lumbar drain. Basic white light 
illumination from the endoscope was used to identify 
the presence of unstained or fluorescein‑tinged CSF 
during the procedure. A dural reconstruction algorithm 
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developed by the authors, based on leak severity and 
location/size of the skull base defect, was used for skull 
base reconstruction. A valsalva maneuver was then 
performed to assess reconstruction integrity and ensure 
no visualization of fluorescein at the conclusion of the 
procedure. Temporary postoperative CSF drainage was 
performed with duration dependent on the treated 
pathology. Lesion type and location, endonasal approach 
corridor, reconstruction method, operative time, and 
presence of postoperative CSF leak were analyzed.
A total of 419 patients were included in this study over 
nearly a 10‑year period at a single institution. Of 269 
patients who had an identified intraoperative CSF leak, 250 
(92.9%) of them had fluorescein‑stained CSF identified 
during the procedure and were labeled as true positives. 
The remaining 19 (7.1%) patients had clear, unstained CSF 
that was identified and were categorized as false negatives. 
There were no false positives. This data generated the 
sensitivity and specificity of low‑dose intrathecal fluorescein 
to detect an intraoperative CSF leak to be 92.9% and 100%, 
respectively. An overall total of 7 (1.7%) patients developed 
a postoperative CSF leak within the 1st month. All of these 
patients were true positives. Lesion type, approach corridor, 
reconstruction method, and operative time were not risk 
factors predictive of a postoperative CSF leak.
Perspective: While retrospective, this well‑organized study 
underscores the significance of intraoperative identification 
of a CSF leak during endoscopic endonasal skull base 
surgery. The authors note that intrathecal fluorescein 
can help identify intraoperative CSF leaks with high 
sensitivity and specificity. The overall false negative rate of 
4.5% was hypothesized to be due to arachnoidal scarring, 
lumbar stenosis, inadequate time for circulation, and/
or unclear physiology. None of the false negative patients 
developed postoperative CSF leaks, substantiating the 
25 mg dosage of fluorescein. No side effects related to 
intrathecal fluorescein were noted. Recognized limitations 
of this study include lack of a randomized controlled study, 
inability to identify patients with small, postoperative leaks 
that spontaneously resolve, and absence of an objective 
measurement tool to assess for intraoperative leaks.
Multiple other high‑volume institutions that perform 
such surgery without routine fluorescein administration 
report similar intraoperative and postoperative CSF 
leak rates while avoiding the infrequent side effects 
of fluorescein, dexamethasone, and diphenhydramine, 
as well as the rare complications of accessing the 
lumbar cistern via needle or catheter. In addition, 
150 of the 419 patients in this article did not have an 
intraoperative CSF leak, negating any potential benefit 
from intrathecal fluorescein. We recognize the advantage 
of intrathecal fluorescein and favor its judicious use to 
help identify unclear leak sites in patients with suspected 
spontaneous or traumatic CSF leaks. Furthermore, we 
have observed that good pulsation of the reconstruction 
at the conclusion of surgery usually confirms a watertight 
closure and may provide an additional objective data 
point to ensure good coverage of an iatrogenic known 
dural defect. A randomized controlled study would be 
needed to provide stronger conclusions on the utility of 
routine intrathecal fluorescein.
Summary Written by: Anand V Germanwala, MD
SPINAL INTRAARTERIAL CHEMOTHERAPY: 
INTERIM RESULTS OF A PHASE I CLINICAL 
TRIAL[1]
Study Question: Is spinal intraarterial chemotherapy 
(SIAC) safe and feasible for the treatment of metastatic 
spinal epidural tumors in patients who have exhausted 
standard therapeutic options?
Patsalides et al. reported the interim outcomes of an 
ongoing single arm prospective Phase I clinical trial 
investigating the role of SIAC for advanced metastatic 
spinal tumors that are no longer candidates for resection 
or radiotherapy. Patients older than 18 years of age with 
metastatic spinal disease causing cord compression on 
imaging disease causing cord compression on imaging 
were included in the study. Determination of those who 
are not candidates for resection or radiotherapy was made 
based on prior consensus among radiation oncologists 
and neurosurgeons. Those with severe cord compression 
where the subarachnoid space was completely occluded 
were excluded. In addition, patients with <3 months life 
expectancy or have the same segmental arteries supplying 
the spinal cord and the tumor on diagnostic angiography 
were excluded. Nine patients with 7 different tumor types 
underwent selective spinal angiography and received 
19 IA treatments of melphalan, an alkylating agent. 
After diagnostic angiography of segmental arteries at the 
level of cord compression, including one level above and 
below, the ventral branch of the segmental arteries were 
occluded with coils to maximize chemotherapy delivery 
along the dorsal branch supplying the tumor while 
minimizing its delivery to adjacent healthy tissue.
Melphalan was chosen based on its established and 
promising IA use in a variety of other malignancies 
including colorectal metastases to the liver and lung 
metastases. Total injected dose was 16 mg/m2, representing 
the recommended systemic dose. Patients were allowed 
up to 3 SIAC procedures in 1 sitting, repeated up to ever 
3 weeks. Patients were followed up with, at minimum, 
one spinal magnetic resonance imaging (MRI) with 
contrast at 4 weeks following SIAC to determine possible 
complications and tumor control. Follow‑up ranged from 
1 to 7 months. One patient experienced neutropenic 
fevers, and no other adverse effects were noted. Only 4/9 
patients received the planned 3 separate IA treatments. 
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While tumor size was stable in 7 and decreased in 1, 
disease progression was noted at spinal levels where SIAC 
was not given.
Perspective: The authors report their experience thus far 
in an ongoing Phase I trial utilizing SIAC for progressive 
spinal metastasis with cord compression in patients 
for which conventional therapies have failed. Although 
advances in microsurgical technique and radiotherapy 
have improved the rates of tumor control for patients 
with metastatic spinal disease, there remains a subset of 
patients that fail or are no long candidates for standard 
therapies. For these patients, prognosis remains grim, 
and innovative treatment modalities are essential, 
as inevitable neurological deterioration secondary to 
progressive cord compression will occur.
Selective IA delivery of chemotherapy offers a number 
of pharmacokinetic advantages of maximizing local drug 
concentration and minimizing systemic toxicity. While its 
use in other malignancies has been reported, this is the first 
report of its application in spinal metastasis. Early results 
are promising, with only 1 incidence of myelosuppression 
and neutropenic fevers. In addition, tumor control at 
the levels treated was seen in all but 1 patient. Indeed, 
efficacy should be interpreted with caution due to short 
length of MRI follow‑up due to advance stage of disease 
in patients. Moreover, the optimization of SIAC for the 
treatment of these metastatic lesions requires further 
investigation. While melphalan has demonstrated efficacy 
by IA route in other cancers, clinical response is likely 
tumor‑dependent, and the present study included a variety 
of metastatic tumor types. Optimal patient selection 
to minimize complications and identification of ideal 
chemotherapeutic agents for differing tumor types requires 
further elaboration from larger data sets. However, despite 
the small study size and limited follow‑up, the study 
highlights SIAC as a novel therapeutic that can benefit 
patients who have exhausted their therapeutic options.
Summary Written by: Winward Choy, BA and Zachary A 
Smith, MD
FAREWELL TO OLIGOASTROCYTOMA: 
IN SITU MOLECULAR GENETICS 
FAVOR CLASSIFICATION AS EITHER 
OLIGODENDROGLIOMA OR 
ASTROCYTOMA[3]
Study Question: What is the impact of molecular 
genetics in glioma classification and the subsequent 
treatment of these patients?
The authors evaluated 43 oligoastrocytoma specimens 
with the presence of the IDH1 R132H mutation as well 
as at least 1 cm2 of intermingled histology. The specimens 
were then evaluated with immunohistochemistry for 
the ATRX and p53 mutations. Fluorescence in situ 
hybridization was used for analysis of the 1p/19q 
co‑deletion. The authors confirmed that all tumors cells 
with p53 or ATRX mutation or 1p/19q co‑deletion also 
stained for the IDH1 R132H mutation. The authors 
identified 30 cases with the IDH1 R132H exclusively in 
histology consistent with oligodendroglioma. This portion 
of the tumor displayed the 1p/19q co‑deletion. In contrast, 
the “astrocytic” portion of these specimens was devoid of 
the ISH1R132H, p53, or ATRX mutations or 1p/19q loss. 
This “astrocytic” portion was consequently inferred to be 
reactive. The authors also identified 11 cases with both 
ATRX and p53 mutations without 1p/19q co‑deletion, 
indicative of an astrocytoma despite some areas of 
oligodendroglial histology. One case displayed 1p/19q 
co‑deletion in both the astrocytic and oligodendroglial 
portions without the ATRX or p53 mutations and was 
interpreted as an oligodendroglioma. The last specimen 
was resected from a patient with a prior history of 
irradiation and displayed the ATRX and p53 mutations 
as well as the 1p/19q co‑deletion in both the astrocytic 
and oligodendroglial portions of the specimen. Of note, 
radiation has previously been associated with p53 and 
ATRX mutations, which may explain the findings in this 
specimen.
Perspective: The authors of this study aim to evaluate 
the diagnosis of oligoastrocytoma via in situ molecular 
genetics. Recent literature establishes that pure 
astrocytomas display mutations in both ATRX and 
TP53, whereas true oligodendrogliomas display 1p/19q 
co‑deletion. Oligodendroglioma patients typically display 
a significantly longer overall survival as compared 
to patients with astrocytoma. This difference partly 
correlates with response to chemotherapy, as seen in 
patients with the 1p/19q co‑deletion. The diagnosis of 
oligoastrocytoma was previously defined by the WHO 
as a mixture of histologic features of astrocytoma and 
oligodendroglioma on histology. However, no guidelines 
exist on the minimal percentage of each subtype 
complicated by the typically minor total tumor fraction 
provided intraoperatively.
This study provides data that delineates between the 
diagnosis of oligodendrogliomas and astrocytoma beyond 
histology alone. Molecular genetics will serve as a key 
component to the diagnosis of gliomas. Recent data from 
such trials as Radiation Therapy Oncology Group 9802 
indicate that patients with WHO Grade II gliomas may 
benefit from chemotherapy and/or radiation. As upcoming 
trials look to study the efficacy of temodar versus 
procarbazine, lomustine, and vincristine chemotherapy in 
lower grade gliomas, differences in outcome in astrocytic 
versus oligodendroglial subtypes using the molecular 
genetic distinctions as described in this study may help 
distinguish the true role of these treatment regimens. In 
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addition, the use of molecular genetics will certainly play 
a key role in differentiating Grade IV from lower grade 
gliomas, which will impact enrollment into future clinical 
trials.
Summary Written by: Jonathan H Sherman, MD
PRENATAL MYELOMENINGOCELE CLOSURE 
AND THE NEED FOR CEREBROSPINAL 
FLUID SHUNT PLACEMENT [4]
Study Question: What are the 1 year outcomes from 
the Management of Myelomeningocele Study (MOMS) 
trial? Are specific risk factors associated with benefit from 
prenatal surgery?
MOMS was a multicenter randomized trial comparing 
both safety and efficacy of prenatal and postnatal closure 
of myelomeningocele (MMC).[1] Pregnant women with a 
fetus prenatally diagnosed with MMC between 19 and 
25 weeks of gestation were randomized at one of the 
3 maternal‑fetal surgery centers to either prenatal or 
postnatal surgical MMC repair. In the trial, the primary 
outcome was defined as a composite of fetal loss or 
any of the following: Infant death, cerebrospinal fluid 
(CSF) shunt placement, or meeting prespecified criteria 
for shunt placement before 1 year of age. In this paper, 
the authors examine primary outcome, actual shunt 
placement, and shunt revision surgery rates for patients 
who underwent prenatal and postnatal repair. The 
criteria for placement of CSF shunt were re‑examined. 
The authors noted that during almost a decade of 
recruitment, the management of pediatric hydrocephalus 
had changed. In the published cohort, about one‑fourth 
of patients in the prenatal surgery group and one‑tenth 
of patients in the postnatal surgery group met the criteria 
for CSF shunt placement, but did not have actual CSF 
shunt placement. This observation led the authors to 
conduct this current investigation (it is important to 
note there was a blinded adjudication process for the 
evaluation of hydrocephalus in the MOMS trial). The 
authors also speculate whether it is possible to identify 
which fetuses are likely or unlikely to benefit from 
prenatal surgery. Logistic regression was used to examine 
for interactions between the type of MMC repair surgery 
and prenatal risk factors for shunt placement. These 
included MMC lesion level, gestational age, amount of 
hindbrain herniation, and ventricle size.
The MOMS trial was stopped early with demonstrated 
efficacy of prenatal surgery when 158 of 183 pregnancies 
were reported. Here, the authors report on results from 
183 pregnancies: 91 women with prenatal surgery and 
92 women randomized to postnatal surgery. Using the 
definition above, the primary outcome occurred in 73% of 
infants in the prenatal surgery group and 98% of infants in 
the postnatal surgery group (P < 0.0001). Actual shunting 
rates were 44% and 84%, respectively (P < 0.0001). For 
the decisions of actual shunt placement, it appeared that 
treating pediatric neurosurgeons incorporated evaluation 
of clinical signs of increased intracranial pressure 
rather than relying on progressive ventriculomegaly on 
radiographic findings alone. The authors revised the 
most commonly met criteria to include overt clinical 
signs of increased intracranial pressure, such as split 
cranial sutures, bulging fontanelle, or sun‑setting 
eyes, in addition to increasing head circumference or 
hydrocephalus. Using these proposed modified criteria, 
only three patients in each group met criteria, but did 
not undergo actual shunt placement. For the revised 
composite outcome, there was a difference between 
the prenatal and postnatal surgery groups: 49.5% versus 
87.0% (P < 0.0001). In the prenatal surgery group, 20% 
of those with ventricle size <10 mm at initial screening, 
45.2% of those with ventricle size of 10–15 mm, and 
79.0% of those with ventricle size ≥15 mm received a 
shunt. In the postnatal group, 79.4%, 86.0%, and 87.5%, 
respectively, underwent CSF shunt placement (P = 0.02). 
Only ventricle size was significantly associated with CSF 
shunt placement or with the revised composite outcome, 
with odds ratios of 1.46 (95% confidence interval [CI] 
1.20–1.79) and 1.57 (95% CI 1.26–1.97), respectively. 
Lesion level, gestational age, sex, and degree of hindbrain 
herniation were not significantly associated with receiving 
CSF shunt on multivariable logistic regression.
Perspective: This study reported on updated results 
from an important randomized trial of prenatal versus 
postnatal surgery for repair of MMC. Of the prenatal 
risk factors that may predict the future need for CSF 
shunt placement, only ventricle size was significantly 
associated with the need for shunting. Larger ventricles 
at initial screening are associated with increased need for 
CSF shunting among those in the prenatal surgery group. 
From this knowledge, the authors conclude that during 
prenatal counseling for parents, care should be exercised 
in predicting beneficial effects on the need for shunting 
after undergoing fetal surgery for MMC in patients with 
ventricles 15 mm or larger at the time of initial screening; 
prenatal surgery does not appear to improve outcome in 
this group. The revised criteria proposed in this study 
may be useful as guidelines for treating hydrocephalus 
in this group. This study found that pediatric 
neurosurgeons are more likely to rely on clinical signs 
of increased intracranial pressure by assessment of the 
anterior fontanelle or cranial sutures than on traditional 
radiological signs of ventriculomegaly or growth of head 
circumference for treating hydrocephalus. This finding 
is in keeping with the body of contemporary pediatric 
neurosurgery literature. Postnatal criteria of surgical 
intervention for hydrocephalus have been evolving, both 
with the practice of permissive ventriculomegaly and 
with the current interest in and evaluation of endoscopic 
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third ventriculostomy/choroid plexus coagulation as an 
attractive alternative to CSF shunting in MMC patients. 
Overall, there appears to be a trend toward reduction 
in CSF shunting rates for patients with MMC in the 
past decade. The field is in evolution, and our new 
understanding is yet to be completely defined.
Summary Written by: Sandi Lam, MD MBA
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